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Abstract
Lung cancer is the leading cause of cancer death worldwide. Although disruption of normal
proliferation and differentiation is a vital component of tumorigenesis, the mechanisms of
this process in lung cancer are still unclear. A transcription factor, C/EBPβ is a critical regu-
lator of proliferation and/or differentiation in multiple tissues. In lung, C/EBPβ is expressed
in alveolar pneumocytes and bronchial epithelial cells; however, its roles on normal lung ho-
meostasis and lung cancer development have not been well described. Here we investigat-
ed whether C/EBPβ is required for normal lung development and whether its aberrant
expression and/or activity contribute to lung tumorigenesis. We showed that C/EBPβ was
expressed in both human normal pneumocytes and lung adenocarcinoma cell lines. We
found that overall lung architecture was maintained in Cebpb knockout mice. Neither over-
expression of nuclear C/EBPβ nor suppression of CEBPB expression had significant effects
on cell proliferation. C/EBPβ expression and activity remained unchanged upon EGF stimu-
lation. Furthermore, deletion of Cebpb had no impact on lung tumor burden in a lung specif-
ic, conditional mutant EGFR lung cancer mouse model. Analyses of data from The Cancer
Genome Atlas (TCGA) revealed that expression, promoter methylation, or copy number of
CEBPB was not significantly altered in human lung adenocarcinoma. Taken together, our
data suggest that C/EBPβ is dispensable for development of lung adenocarcinoma.
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Introduction
Lung cancer is one of the major cancers with more than 220,000 new cases annually in the
United States [1]. Lung cancer is histologically classified into two categories: small-cell lung
cancer (SCLC) and non-small-cell lung cancer (NSCLC). NSCLC is further classified into three
major categories: squamous-cell carcinoma (approximately 30% of all lung cancers), large-cell
carcinoma (10–15%) and adenocarcinoma (30–40%) [2]. Although tobacco smoking is consid-
ered the dominant cause of lung cancer, in particular SCLC and squamous-cell carcinoma, ap-
proximately 10% of lung cancers occur in never smokers [3]. At a molecular level, somatic
mutations that inactivate tumor suppressors (e.g., p53) or constitutively activate signaling mol-
ecules (e.g., Kras and epidermal growth factor receptor [EGFR]) have been identified during
the last three decades. Additional factors include epigenetic changes and altered expression of
microRNA [4, 5]. These oncogenic events lead to changes in transcription patterns, resulting in
a block in differentiation, suppression of apoptosis, and uncontrolled proliferation [6].
Given that normal lung development is tightly and precisely controlled by complex tran-
scriptional networks, it has been postulated that deregulation of crucial transcription factors
can lead to tumorigenesis [7]. Recently, we and others have shown that C/EBPα, a transcription
factor essential for proper lung development, is required for differentiation from alveolar type
II (AT-II) to alveolar type I (AT-I) cells and that lack of C/EBPα promotes lung adenocarcino-
ma development [8, 9]. As re-expression of C/EBPα leads to proliferation arrest, differentia-
tion, and increased apoptosis accompanied by morphological changes, it suggests that loss of
C/EBPαmay contribute to lung cancer development in humans [10, 11]. However, roles of
other members of C/EBP family on lung development and tumorigenesis have not been
well characterized.
C/EBPβ is a critical regulator of proliferation and/or differentiation in multiple cells/tissues,
including myeloid cells, liver, adipose tissues, the immune system, mammary gland and uterus
[12–18]. C/EBPβ is known to have three isoforms, which are products of a single mRNA by a
leaky ribosomal scanning mechanism [19]. In humans, the full protein and liver-enriched acti-
vator protein (LAP) act as activators, whereas liver-enriched inhibitory protein (LIP), the
N-terminal truncated form LIP can attenuate the transcriptional activity as it lacks part of the
transactivation domain [20]. Therefore, the ratio of their isoforms can determine transcription-
al activity [20].
In rodents, C/EBPβ is expressed in alveolar epithelial cell [21] and the bronchiolar epitheli-
um [22]. It has been shown that mice lacking C/EBPβ show no abnormalities in lung function
or morphology at perinatal stage [23, 24]; however, its role on adult lung homeostasis or lung
cancer development has not been well characterized. Here we sought to determine whether
C/EBPβ plays an important role on lung maintenance at adult stage and whether aberrant ex-
pression/activity of C/EBPβ contributes to lung cancer development, specifically in a lung
adenocarcinoma model.
Materials and Methods
Cell lines and culture
All cell lines used in this study (293T, A427, A549, NCI-H125, NCI-H358, NCI-H460, NCI-
H1299, NCI-H1395, NCI-H1650, NCI-H1755, NCI-H1975, NCI-H3255, HCC827, PC9, and
BEAS-2B cells) were purchased from the American Type Culture Collection. To examine the
expression of C/EBPβ upon EGF exposure, A549 and NCI-H1975 were plated at 1x105 cells
per mL in 6-well plates and allowed to grow overnight, and then cells were treated with 100 ng/
mL EGF in the presence or absence of either 1 μM erlotinib or 1 μM afatinib for 24 hours. For
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the generation of the cell lines with conditional C/EBPβ expression, NCI-H358 cells were trans-
fected with pBabePuro vector or pBabePuro C/EBPβ-ER and puromycin resistant clones were
selected as previously described [25]. Cells were maintained in phenol red free RPMI1650 sup-
plemented with 10% charcoal-dextran–stripped fetal bovine serum. The presence of the fusion
protein C/EBPβ-ER was screened by western blot analysis using C/EBPβ antibody (C-19: sc-
150). To generate cells transduced with shRNA-mediated suppression of CEBPB, NCI-H358
and NCI-H1975 cells were retrovirally infected with shRNA constructs against CEBPB
(pNa-ntxC/EBPβ) or luciferase gene (control) and sorted for GFP positive cells as previously
described [26].
Mice
The protocol was approved by the Institutional Animal Care and Use Committee at Beth Israel
Deaconess Medical Center (Protocol Number: 022–2012). EGFR-L858R-T790M (EGFRTL)/CCSP-
rtTA bi-transgenic mice and C/EBPβ knockout mice were previously reported [27, 28]. EGFRTL
and CCSP-rtTA genotyping were performed as described previously [27]. C/EBPβ knockout mice
were genotyped by using following primers: Forward primer; 5’GGCAGC TGC TTGAACAAG
TTC 3’, Reverse primer 1; 5’GGCAGC TGC TTG AACAAG TTC 3’, Reverse primer 2; 5’ CAT
CAGAGCAGC CGA TTG TC 3’. PCR reactions were done as follows: 94°C denaturation for
5 min, followed by 35 cycles of 94°C for 40 sec, 58°C for 40 sec, 72°C for 40 sec, followed by a 10
min extension at 72°C. Wildtype and knockout alleles generate 221 bp and 396 bp, respectively. To
induce EGFRTL expression, mice were fed with a doxycycline diet (Harlan Laboratories) up to
12 weeks. Lungs were isolated from treated mice which were euthanized by CO2. Maximum tumor
volume did not exceed 1,000 mm3. A total of 39 mice were used in this study.
Cell lysate preparation andWestern blotting
Cell lysates were prepared as previously described [29, 30]. Briefly, cells were washed with PBS
and centrifuged at 1500 rpm for 5 minutes. Cell pellets were resuspended in 30–60 μL cell lysis
buffer (20 mM Tris-HCl (pH 7.5), 150 mMNaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton,
1 mM β-glycerophosphate, 1 mMNa3VO4, 1 mMNaF, Protease inhibitor cocktail set III (EMD
Millipore), and 1 mM phenylmethanesulfonyl fluoride). Lysates were cleared by centrifugation
(14,000 rpm for 15 minutes in a pre-cooled centrifuge) and boiled with SDS sample buffer for
3 minutes. Protein lysates (20–40 μg) were subjected to SDS polyacrylamide gel electrophoresis
and blotted on to PVDF membranes (Millipore). We purchased C/EBPβ antibody (C-19) from
Santa Cruz Biotechnology (sc-150) and β-actin antibody from Sigma-Aldrich (A3854). Quanti-
tative analysis of relative protein was performed using ImageQuant software (GE Healthcare).
Immunohistochemical analysis
Lungs isolated from mice were fixed in 10% neutral buffered formalin, embedded in paraffin,
sectioned, and stained with H&E. Immunohistochemical staining was performed on formalin-
fixed paraffin sections after antigen retrieval, with the antibodies against TTF-1 (Abcam:
ab40880) followed by incubations with biotinylated secondary antibody (Jackson ImmunoRe-
search), advin-biotin complex (Vector Laboratories), and 3, 3’-diaminobenzidine (Sigma-
Aldrich).
Immunofluorescence analysis
NCI-H358 cells expressing pBabePuro vector or pBabePuroC/EBPβ-ER were treated with 1
μM β-estradiol or 0.1% ethanol (vehicle) for 24 hours and stained with anti ERα antibody
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(Santa Cruz Biotechnology: sc-542) and visualized by Alexa Fluor 488 (Life Technologies). The
slides were mounted in Vectashield mounting medium containing DAPI (Vector
Laboratories).
Luciferase reporter gene assay
To measure C/EBPβ transactivation, A549 cells and NCI-H1975 cells were plated at 1x105/mL
in 24-well plate and incubated overnight. The following day, cells were transiently transfected
with 500 ng C/ebpb0.3-luc reporter (a gift from Dr. Daniel Tenen) [25] and 10 ng pCMV-
Renilla plasmid using 1.0 μL TransIT-X2 reagent (Mirus Bio LLC) according to the instruc-
tions. The medium was replaced by fresh medium containing 100 ng/mL EGF (Peprotech) or
PBS after 6 hours of incubation. The cells harvested with 100μL Passive Lysis Buffer Reporter
after 24 hours of treatment with EGF (or PBS) were subjected to reporter assays using the
Dual-Luciferase Assay reporter system (Promega. Luciferase activities were normalized against
Renilla luciferase activity, and the relative luciferase activity was calculated against PBS control.
Cell Growth Assay
Cell growth was assessed by CellTiter 96 AQueous One solution proliferation kit (Promega) ac-
cording to manufacturer’s instruction. Briefly, cells were plated in 96 well plates at 2,000 cells/
100 μl/well and incubated in 5% CO2 for 72 hours. Twenty μl/well of CellTiter 96 AQueous
One solution was added and incubated in 5% CO2 for 1–4 hours. The absorbance at 490 nm
was measured with the Victor 3 microplate reader (PerkinElmer).
Expression data analyses
Expression datasets from normal human tissues were obtained through Genotype-Tissue Ex-
pression (GTEx) project (https://www.gtexportal.org/home) and the distribution of CEBPB ex-
pression for each tissue type was depicted with a box plot and rank ordered by average
expression. Normalized expression datasets as RSEM (RNA-seq.V2) from primary lung adeno-
carcinoma samples obtained through the Cancer Genome Atlas (TCGA) project (https://tcga-
data.nci.nih.gov/tcga/tcgaHome2.jsp) were log2 (+1) transformed and the distribution of
CEBPB, CEBPA, or CDKN2A expression was plotted as well as depicted as box plot. Correla-
tion of CEBPB expression with its methylation data (HM450) and its copy number data (SNP
6.0) from TCGA data were obtained and analyzed through cBioPortal (http://www.cbioportal.
org/public-portal).
Statistical analysis
Differences between the experimental groups were tested with Student’s t-test. P-values of less
than 0.05 were considered statistically significant.
Results
C/EBPβ is expressed in normal lung and adenocarcinoma cell lines
C/EBPβ regulates cellular proliferation and differentiation under normal physiological condi-
tions. Thus, to confirm C/EBPβ is expressed in human lungs as well as rodent lungs [21, 22],
we examined its expression level from various human organ systems from GTEx datasets. We
found that CEBPB is expressed in human lung at a lower level than hematopoietic system but a
level comparable to or higher than that in any other tissues examined (Fig. 1A). At a protein
level, we also found that C/EBPβ expression was readily detected in BEAS-2B immortalized
human bronchial epithelial cells [31] and a panel of human adenocarcinoma cell lines at
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variable but equivalent level (Fig. 1B). These results indicate that C/EBPβ is expressed in both
benign and malignant cells of the lung.
C/EBPβ knockout mice have normal lung appearance and structure
Cebpb knockout mice have been reported to manifest no histological abnormalities in the lung
at perinatal stage [23, 24]. Therefore, we sought to determine whether C/EBPβ is required for
development and maintenance of lung at later adult stage. Lungs were isolated from Cebpb
knockout and control mice up to 10 weeks of age. We confirmed C/EBPβ was not expressed in
the lungs of Cebpb knockout mice (Fig. 2A), but gross appearance of the lungs was indistin-
guishable from those of Cebpb wild type mice (data not shown). Histological analysis revealed
Fig 1. C/EBPβ is expressed in human lung cells. (A) Expression ofCEBPB in various human tissues in the dataset from GTEx project. RPKM values were
log2 transformed and presented as a box plot for each tissue type. (B) Protein extracts were isolated from a panel of human lung adenocarcinoma cell lines
as well as an immortalized human bronchoepithelial cell line, BEAS-2B and subjected to Western blotting.
doi:10.1371/journal.pone.0120647.g001
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scattered parenchymal lymphoid aggregates in 7 out of 8 (87.5%) lungs isolated from Cebpb
knockout mice, while no such aggregates were observed in ones from wild type siblings (0/10;
0%). However, no major difference in lung parenchymal architecture was apparent between C/
EBPβ knockout and wild type mice (Fig. 2B).
C/EBPβ had no advantageous effects on cell growth in lung
adenocarcinoma cells
Expression of C/EBPβ in lung adenocarcinoma cell lines (Fig. 1B) and its reported proliferative
role in epithelial cancer development [32] prompted us to hypothesize that C/EBPβmay be im-
portant for lung cancer progression. To examine proliferative effects of C/EBPβ, we generated
stable NCI-H358 cell lines expressing an estrogen receptor hormone-binding domain fused to
C/EBPβ (C/EBPβ-ER) or expressing the estrogen receptor hormone-binding domain alone
[25, 26]. Upon stimulation with β-estradiol, C/EBPβ-ER is translocated to the nucleus
(Fig. 3A) and activated(Fig. 3B)Fig. Unexpectedly, nuclear translocation of C/EBPβ-ER to the
nucleus led to suppression of cell proliferation in NCI-H358 cells (Fig. 3C). Next, to examine
requirement of C/EBPβ expression in lung adenocarcinoma cells, we transduced NCI-H358
cells with retrovirus containing shRNA constructs against C/EBPβ and isolated three clones.
Despite greater than 90% reduction in C/EBPβ expression achieved in all clones (Fig. 3D), we
observed no significant difference in cell proliferation upon C/EBPβ suppression in NCI-H358
cells (Fig. 3E). Similar results were obtained in NCI-H1975 cells (data not shown). These re-
sults suggest that C/EBPβ is not essential for and does not promote lung cancer cell growth.
C/EBPβ activity is not mediated by EGFR signaling in lung cancer cells
In breast cancer, EGF stimulation has been shown to reduce C/EBPβ activity by increasing LIP
[33]. Therefore, we asked whether C/EBPβ activity can be regulated by the EGFR signaling
Fig 2. Deletion ofCebpb has no effect on lung structure, but leads to aggregation of lymphoid cells in the lung. (A) Immunoblots of lung extracts from
Cebpb+/+ or Cebpb-/-mice. Note that the predominant isoform expressed in mouse lungs is LAP and C/EBPβ expression in the lung is effectively lost in
Cebpb-/-mice. (B) Representative images of hematoxylin and eosin staining of lungs isolated from Cebpb+/+ (I and II) andCebpb-/- (III and IV) mice. We
analyzed 10Cebpb+/+ and 8 Cebpb-/- mice. Scale bars = 500 μm (I and III) and 100 μm (II and IV). Arrows indicate scattered lymphocyte aggregates in the
lung parenchyma of a Cebpb-/-mouse. No gross or histologic architectural abnormalities were observed in the lungs of Cebpb-/-mice.
doi:10.1371/journal.pone.0120647.g002
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Fig 3. C/EBPβ fails to contribute to cell proliferation in vitro. (A) Fluorescent images of NCI-H358 cells stably expressing C/EBPβ-ER. Cells were treated
with 1 μM β-estradiol or 0.1% ethanol (vehicle) for 24 hours and stained with anti ER antibody and visualized by Alexa Fluor 488. Scale Bar = 10 μm. (B)
Luciferase assay to determine C/EBPβ transcriptional activity in NCI-H358 cells stably expressing C/EBPβ-ER and control cells. Cells were transfected with
C/ebpb0.3-luc reporter and pCMV-Renilla control plasmid were assayed after 24 hours of treatment with 1 μM β-estradiol or vehicle control. Data represents
mean ± standard deviation from three independent experiments. ** denotes p 0.01. (C) Cell viability determined by MTS assay. NCI-H358 cells
expressing C/EBPβ-ER cells or control cells were plated in 96 well plates at 2,000 cells/well and assayed after 72 hours of incubation. Data represents mean
± standard deviation from eight independent experiments. * denotes p 0.05. (D) Immunoblots of C/EBPβ in NCI-H358 cells transduced with shRNA against
CEBPB. Three clones each for control and shRNA against CEBPB are shown. (E) Cell viability determined by MTS assay. NCI-H358 cells transduced with
shRNA againstCEBPB or control shRNA described in (D) were plated in 96 well plates at 2,000 cells/well and assayed after 72 hours of incubation. Data
represents mean ± standard deviation from three independent experiments. N.S. denotes not significant.
doi:10.1371/journal.pone.0120647.g003
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pathway in the lung cancer cells. To this end, we examined two cell lines, NCI-H1975 and
A549 cells, which harbor the EGFR L858R+T790M double mutations and KRAS G12Smuta-
tion, respectively. When these cells were treated with EGF in the presence or absence of EGFR
tyrosine kinase inhibitors (erlotinib or afatinib), no apparent changes in expression of C/EBPβ
LIP isoform were detected (Fig. 4A). Consistent with these results, EGF stimulation led to no
significant change in C/EBPβ activity determined by luciferase assay in these two cell lines
(Fig. 4B). Therefore, it appears unlikely that EGFR signaling mediates C/EBPβ activity in lung
cancer cells.
C/EBPβ is dispensable for lung tumorigenesis in the EGFRmutant-
driven murine lung cancer model
Our results from lung cancer cell lines suggest that C/EBPβ in tumor cells may not drive cell
growth. However, these results should be confirmed in vivo. In addition, it is possible that C/
EBPβ play an important role to maintain tumor microenvironment. Therefore, we generated
the inducible EGFR T790M-L858R transgenic mouse model in Cebpb knockout background.
We crossed two established mouse models, the lung specific EGFR-L858R-T790M (EGFRTL)/
CCSP-rtTA bi-transgenic mice [27], and the C/EBPβ conventional knockout mice (Cebpb-/-)
(Fig. 5A and 5B) [28]. Consistent with our previous report [27], TTF-1 positive lung adenocar-
cinomas developed in EGFRTL/CCSP-rtTA/Cebpb+/+mice (Fig. 5C; I and II) as well as in
EGFRTL/CCSP-rtTA/Cebpb-/-mice (Fig. 5C; III and IV) when treated with doxycycline for
10 weeks. By histological analysis, the lung adenocarcinomas in EGFRTL/CCSP-rtTA/Cebpb-/-
mice tended to demonstrate a more central bronchial papillary growth pattern (Fig. 5C; III),
whereas the adenocarcinomas in EGFRTL/CCSP-rtTA/Cebpb+/+mice tended to have a more pe-
ripheral distribution with solid and bronchioalveolar growth features (Fig. 5C; I). However, no
significant differences were noted regarding overall tumor burden as reflected by gross lung
weights (Fig. 5D). These data suggest that C/EBPβ is dispensable for lung tumorigenesis in
EGFR-driven murine lung cancer.
Fig 4. EGF does not increase LIP protein. (A) Immunoblots of C/EBPβ in NCI-H1975 (EGFR L858R+T790M) and A549 (KRASG12S) lung
adenocarcinoma cells treated with EGF in the presence or absence of EGFR kinase inhibitors for 24 hours. Changes in LIP expression are adjusted by β-
actin expression and expressed as fold increase relative to that of PBS-treated cells. Note that the full and LAP forms were detected in the gel exposed for 15
seconds, whereas LIP forms were detected after 1-hourr exposure of the gel. (B) Luciferase assay to determine C/EBPβ transcriptional activity. NCI-H1975
and A549 cells transfected with C/ebpb0.3-luc reporter and pCMV-Renilla control plasmid were assayed after 24 hours of treatment with EGF or PBS control.
Data represents mean ± standard deviation from four independent experiments. N.S. denotes not significant.
doi:10.1371/journal.pone.0120647.g004
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Fig 5. Deletion ofCebpb does not affect tumor burden in vivo. (A) Scheme of the strategy generating lung specific inducible EGFR-TL transgenic mice
with Cebpb knockout background. (B) Genotype of EGFRTL/CCSP-rtTA/Cebpb+/+, CCSP-rtTA/Cebpb+/+ and EGFRTL/CCSP-rtTA/Cebpb-/- mice. (C)
Representative images of H&E staining and immunohistochemistry of lungs isolated from EGFRTL/CCSPrtTA/Cebpb+/+(I and II) or EGFRTL/CCSPrtTA/
Cebpb-/-(III and IV). Lung sections were stained with H&E (I and III) and anti-TTF1 (II and IV) antibodies. “A” indicates an area with bronchioalveolar growth
pattern and “P” indicates an area with bronchial papillary growth pattern. (D) Lung weight isolated frommice treated with doxycycline for 8–12 weeks. We
analyzed 5CCSP-rtTA/Cebpb+/+, 5 EGFRTL/CCSP-rtTA/Cebpb+/+, and 11 EGFRTL/CCSP-rtTA/Cebpb-/-mice. Data represent mean ± standard deviation.
** denotes p 0.01. N.S. denotes not significant.
doi:10.1371/journal.pone.0120647.g005
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C/EBPβ is neither overexpressed nor downregulated in human lung
adenocarcinoma
Lastly, we sought to determine whether C/EBPβ expression is altered in human lung adenocar-
cinoma using data from The Cancer Genome Atlas (TCGA). We confirmed that two tumor
suppressors, CEBPA and CDKN2A, were downregulated in a subset of human lung adenocarci-
nomas as previously described [34, 35]. Compared to these two genes, expression of CEBPB
was maintained in these tumor samples (Fig. 6A). Next, we examined the methylation status of
the CEBPA and CEBPB promoters. The CEBPB promoters were unmethylated in all lung ade-
nocarcinoma samples with available methylation data (n = 185), whereas the CEBPA promoter
regions were frequently aberrantly methylated, consistent with previous results [36] (Fig. 6B).
By examining the matched copy number data, we found that the CEBPA and CEBPB loci were
not subject to frequent deletion (Fig. 6C). Taken together, these data suggest that expression of
C/EBPβ is not altered in human lung adenocarcinoma.
Discussion
C/EBP proteins consist of a group of basic-leucine zipper (bZIP) transcription factors which
are involved in the regulation of important functions such as proliferation and differentiation,
survival and apoptosis, oncogene-induced senescence and tumorigenesis, inflammation, im-
munity, and metabolism [37]. In this study, we investigated the role of C/EBPβ on
lung adenocarcinomagenesis.
C/EBPα and C/EBPβ reportedly play partly overlapping roles in some tissues. Knock-in
mice where the C/EBPα gene function is replaced by that of C/EBPβ partly rescues the hemato-
poietic phenotype of the C/EBPα knockout mice, providing evidence that C/EBPβ could com-
pensate for loss of C/EBPα in hematopoiesis [38]. However, C/EBPβ seems to have more
complex roles as it can act as either a promoter or an inhibitor to cell proliferation under the
different cellular contexts or tissues [33]. C/EBPβ is up-regulated during macrophage differen-
tiation [18], indicating that C/EBPβ shows anti-proliferative and differentiation-inducing func-
tion similar to C/EBPα. On the other hand, partial hepatectomy leads to increased expression
of C/EBPβ, suggesting that C/EBPβ is required for hepatocyte proliferation [15]. Although
both C/EBPα and C/EBPβ are expressed in pulmonary cells in rodents [21, 22] and humans
(Fig. 1A), it is unlikely that C/EBPβ is involved in normal lung homeostasis as there was no
striking difference in lung architecture between wild type and Cebpb knockout mouse at adult
stage (Fig. 2B). However, C/EBPβ can be upregulated in the lung together with C/EBPδ when
challenged with acute-phase stimuli [39]. In this regard, it is notable that scattered parenchy-
mal lymphoid aggregates were frequently observed in lungs isolated from Cebpb knockout
mice (Fig. 2B: IV) possibly due to upregulation of IL-6 in Cebpb knockout mice [28]. As infil-
trated lymphocytes may regulate neutrophil recruitment during acute lung injury [40], it is
possible that C/EBPβmay play a role to resolve acute inflammation by suppressing accumula-
tion of lymphoid cells. These questions remain to be addressed.
Based on our observation that C/EBPβ was expressed in lung adenocarcinoma cell lines
(Fig. 1B), we hypothesized that C/EBPβmay contribute to lung cancer development. Although
C/EBPα has been established as a cell cycle inhibitor/tumor suppressor [41], several lines of ev-
idence suggest that the role of C/EBPβ in tumorigenesis seems to be tissue-specific. All-trans
retinoic acid induces differentiation of acute promyelocytic leukemia (AML) cells via C/EBPβ
expression [25]. Overexpression of C/EBPβ in HepG2 hepatocellular carcinoma cells strongly
inhibits tumor cell proliferation. On the other hand, C/EBPβ is highly expressed and was asso-
ciated with tumor progression in colorectal and ovarian cancers [42, 43]. Furthermore, deletion
of Cebpb in keratinocytes protects carcinogen-induced skin tumorigenesis [32]. In the current
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study, neither overexpression of nuclear C/EBPβ nor suppression of CEBPB expression showed
evidence that supports tumor promoting or suppressive role of C/EBPβ (Fig. 3). Furthermore,
unlike in breast cancer cells [33], LIP protein and C/EBPβ activity upon EGF stimulation were
unchanged in lung adenocarcinoma cell lines (Fig. 4), indicating that C/EBPβmay not be in-
volved in proliferation in response to growth factor stimulation. These in vitro data was sup-
ported by our in vivomouse model (Fig. 5) and clinical data (Fig. 6).
Fig 6. C/EBPβ is not altered in human lung adenocarcinoma. (A) mRNA expression of CEBPA, CEBPB, andCDKN2A in TCGA lung adenocarcinoma
dataset. RSEM values obtained from TCGA data were log2 transformed and depicted as individual dots representing a sample and box plot. (B) Methylation
status in CEBPA andCEBPB promoter regions in TCGA lung adenocarcinoma dataset. Scatter plot depicts mRNA expression in Y-axis and methylation level
of the promoter region in X-axis of CEBPA andCEBPB genes. (C) Copy number estimates of CEBPA andCEBPB gene loci in TCGA lung adenocarcinoma
dataset. Scatter plot depicts mRNA expression in Y-axis and copy number estimates in log2 scale in X-axis of CEBPA andCEBPB genes.
doi:10.1371/journal.pone.0120647.g006
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Notably, however, lung adenocarcinomas from EGFRTL/CCSP-rtTA/Cebpb-/- mice show a
propensity to form papillary tumors in the bronchial airways (Fig. 5C; III). Given that there are
no gross or histologic differences in lung architecture or epithelial differentiation observed in
Cebpb knockout lungs [24], it is plausible that environmental alternations led by disruption of
Cebpbmay have affected this histological phenotype. One possibility is that IL-6 may be in-
volved in cell fate conversion efficiency. As described above, IL-6 is shown to be upregulated in
Cebpb knockout mice [28] and can lead to regeneration of airway ciliated cells from basal stem
cells [44]. In addition, inflammatory cytokines including IL-6 can promote de-differentiation
of tumor cells into progenitor cells in hepatocellular carcinoma [45]. Therefore, alterations of
cytokine expression induced by deletion of Cebpbmay have influenced the observed cell types
in lung adenocarcinomas.
In summary, we confirmed that overall lung architecture was maintained in Cebpb knock-
out mice. While C/EBPβ was expressed in human adenocarcinoma cell lines, neither overex-
pression of nuclear C/EBPβ nor knockdown of CEBPB had significant effect on cell
proliferation. Deletion of Cebpb had no impact on lung tumor burden in a murine lung cancer
model. Expression of CEBPB was not altered in human lung cancer samples. Taken together,
our data indicate that C/EBPβ largely is not essential for lung homeostasis or development of
lung adenocarcinoma.
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